The European Commission has approved lenalidomide, ibrutinib, and also temsirolimus (mTOR inhibitor), and for the treatment of mantle cell lymphoma, the other agents aforementioned have not yet been approved for MCL in the European Union. This evidence concerns the gene MTOR and mantle cell lymphoma.